CCIA
SPRO icon

Campbell & Co Investment Adviser’s Spero Therapeutics SPRO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-23,900
Closed -$440K – 805
2021
Q3 		$440K Buy
+23,900
New +$384K 0.14% 254

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Campbell & Co Investment Adviser's SPRO Position: Q4 2021 in Review

Campbell & Co Investment Adviser sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 23,900 shares — an estimated $440K sold.

Campbell & Co Investment Adviser first reported a position in SPRO in Q3 2021 and held it in 1 quarter. The position peaked at $440K in Q3 2021. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • Campbell & Co Investment Adviser reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 23,900 Spero Therapeutics shares in Q4 2021, an estimated $440K.
  • Campbell & Co Investment Adviser first reported a position in Spero Therapeutics in Q3 2021 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Spero Therapeutics position peaked at $440K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2021, filed 10 Feb 2022.